Canine Lymphoma: Welfare During Chemotherapy in 2026

Lymphoma is one of the most common cancers in dogs, and chemotherapy protocols achieve remission in most cases with welfare outcomes that differ significantly from human chemotherapy experience.

Key Facts

Lymphoma accounts for approximately 10-15% of all canine cancers and is the most common haematopoietic tumour
CHOP-based chemotherapy achieves complete remission in approximately 80-90% of treated dogs
Dogs tolerate chemotherapy significantly better than humans, with most maintaining appetite and normal activity
Median survival with CHOP chemotherapy is 12-14 months, with 20-25% of dogs surviving over 2 years

Welfare Considerations

Canine lymphoma chemotherapy has a dramatically different welfare profile from human cancer treatment. Dose protocols are calibrated to achieve remission while maintaining quality of life — most dogs experience mild, transient side effects rather than the severe adverse events common in human oncology. Dogs in remission maintain normal appetite, activity, and social behaviour. Quality of life during chemotherapy compares favourably to untreated disease. Regular quality of life assessment at every treatment visit enables dose modification and early detection of welfare deterioration. The goal is maintaining good daily life, not cure — an important framing for owner expectations and welfare monitoring.

What You Can Do

Consult a veterinary oncologist to discuss whether CHOP chemotherapy is appropriate for your dog
Use validated quality-of-life tools at every treatment visit to monitor welfare throughout chemotherapy
Learn to recognise adverse event signs (vomiting, anorexia, lethargy) and contact your oncologist promptly
Understand that the goal of canine lymphoma chemotherapy is remission and quality of life, not curative intent